Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 5/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 5/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 5/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KCNQ5 | Q9NR82 | 2/20 | 0.35 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.35 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | MTHFD1 | P11586 | 1/20 | 0.34 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 3/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17641571 | 0.78 | SYK (0.43) | SYK | |
| SCHEMBL16164683 | 0.77 | KCNQ3 (0.41) | BACE1KCNQ3KCNQ2NPC1RAB9A | |
| SCHEMBL17512555 | 0.76 | KCNQ3 (0.42) | BACE1KCNQ3KCNQ2NPC1RAB9A | |
| SCHEMBL4326940 | 0.74 | DPP4 (0.39) | BACE1SYK | |
| SCHEMBL30641925 | 0.74 | DPP4 (0.39) | BACE1SYK | |
| Hydrochloric Acid SCHEMBL28375765 | 0.73 | DPP4 (0.39) | BACE1SYK | |
| SCHEMBL19459214 | 0.73 | ADORA1 (0.36) | NPC1RAB9AALDH1A1 | |
| SCHEMBL17641569 | 0.73 | IDO1 (0.36) | SMN1; SMN2ALDH1A1SYK | |
| SCHEMBL25394963 | 0.72 | BTK (0.37) | BACE1KCNQ3KCNQ2NPC1RAB9A | |
| SCHEMBL15921542 | 0.72 | MALT1 (0.43) | JAK2JAK1KCNQ3KCNQ2KCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167280-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-01 | — | — | US | disclosed |
| US-20170291892-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167280-B2 | Substituted oxopyridine derivatives | OGFOD1, PNPO, VASP | BACE1 4213/4885JAK2 324/4885JAK1 600/4885 |
| US-20170291892-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, PNPO, VASP | BACE1 4213/4885JAK2 324/4885JAK1 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.